Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS) — Stock Score Summary

Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS) has a MoatMap StockRank of 53/100 based on Quality (70/100), Value (30/100), and Momentum (39/100) factor scores. The current signal is HOLD. Chengdu Easton Biopharma is a Chinese generic and specialty pharmaceutical company. It is a casualty of the CDMO pricing power cycle, as it lacks its own proprietary manufacturing scale and is squeezed by high input costs and domestic volume-based procurement (VBP) price cuts.

Chengdu Easton Biopharmaceuticals Co., Ltd. develops, manufactures, and markets generic and innovative drugs, focusing on anesthesia, analgesia, and cardiovascular therapies. The company holds a strong market position in China's clinical anesthesia segment with a robust pipeline of complex generics. It is a vertically integrated pharmaceutical company combining active pharmaceutical ingredient (API) production with finished dosage forms.

Key Financial Metrics

Price$6.75
Market Cap$1.4B
P/E (TTM)29.83
P/E (Forward)22.55
Price/Book2.75
Return on Equity8.8%
Return on Invested Capital9.5%
Debt/Equity2.64
Gross Margin74.4%
Operating Margin12.5%
Revenue Growth6.7%
Dividend Yield1.1%
Free Cash Flow$3M

Chengdu Easton Biopharmaceuticals Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Chengdu Easton Biopharmaceuticals Co., Ltd.’s (688513.SS) StockRank?
MoatMap’s StockRank for Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS) is 53/100, with a Hold signal. It is a composite of Quality (70), Value (30), and Momentum (39) factor ranks across MoatMap’s 19,000+ stock universe.
Does Chengdu Easton Biopharmaceuticals Co., Ltd. have an economic moat?
Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS) has a Quality factor score of 70/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Chengdu Easton Biopharmaceuticals Co., Ltd. a buy, hold, or sell?
MoatMap’s current signal for Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS) is Hold, based on a StockRank of 53/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Chengdu Easton Biopharmaceuticals Co., Ltd. in?
Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS) operates in the Healthcare sector, specifically the Biotechnology industry (China).
Browse all ranked stocks688513.SS deep dive reportAI ChampionsHow we score stocksSense-check another stock